Cat: IPD-X21372

Recombinant Cynomolgus FGL1 Protein(HEK293), hFc

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • Gene name

    FGL1

  • 简介

    FGL1 is a specific hepatocyte mitogen, regulates the expression of proliferative factors, promoting liver regeneration and repairing liver injury. FGL1 inhibits T-cell activation by binding to LAG3. FGL1 promotes cell proliferation by activating the ERK/p-ERK pathway. FGL1 inhibits apoptosis of non-small cell lung cancer (NSCLC) cells by inhibiting PARP1/caspase 3 pathway. FGL1 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived FGL1 protein, expressed by HEK293 , with C-hFc labeled tag.

  • Application

    SPRMSTBLIITCELISACELL ASSAYDRUG SCREENING

  • Biological Activity

    Human LAG-3 immobilized on CM5 Chip can bind Cynomolgus FGL1 with an affinity constant of 5.358 μM as determined in a SPR assay. Human LAG-3 immobilized on CM5 Chip can bind Cynomolgus FGL1 with an affinity constant of 5.358 μM as determined in a SPR assay.

  • Alternative Names

    Fibrinogen-like protein 1; FGL1; HP-041; Hepassocin; HFREP-1; LFIRE-1

  • Species

    Cynomolgus

  • Source

    HEK293

  • Tag

    C-hFc

  • Purity

    Greater than 90% as determined by SDS-PAGE.

  • Uniprot

    XP_005562748.1

  • Expression Region

    M37-I348

  • Protein Length

    Partial

  • Molecular Weight

    56.94 kDa.

  • Endotoxin

    < 1.0 EU per μg protein as determined by the LAL method.

  • Form

    Freeze-dried powder

  • Buffer formulation

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • Reconstitution

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • Customization

    Site-directed mutagenesis Custom tag design Custom buffer formulation Custom full-length protein production

  • Stability Test

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • Storage & Shelf Life

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • Shipping

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

FGL1, or Fibrinogen-like protein 1, is a member of the fibrinogen-related protein family that plays a crucial role in various biological processes, including immunoregulation, inflammation, and tumor progression. It has garnered significant attention in recent years due to its dual function in modulating both immune responses and tumor microenvironments. Elevated FGL1 expression has been correlated with poor prognosis in several types of cancer, suggesting its potential as a biomarker for disease progression and a target for therapeutic intervention. Research has shown that FGL1 can inhibit T cell activation and promote immune evasion by tumors, highlighting its role in the suppression of anti-tumor immunity. Moreover, FGL1 has been implicated in facilitating tumor growth and metastatic spread. Consequently, the development of FGL1 recombinant proteins aims to elucidate its mechanisms of action, assess its functional characteristics, and explore its potential in clinical applications, particularly in oncology and immunotherapy. By gaining a deeper understanding of FGL1's role in immune modulation and tumor dynamics, researchers hope to harness its properties for novel therapeutic strategies, enhancing the efficacy of existing treatments and improving patient outcomes. This background lays the foundation for ongoing studies focusing on FGL1's interactions within the immune system, its structural and functional properties, and the feasibility of targeting FGL1 in therapeutic contexts.

E-mail

sales@ipodix.com

Sales

+1 2092920560


Contact us via WhatsApp

IPODIX Biotech Inc

2108 N ST, STE N
Sacramento, CA 95816, USA

For Product Information and Orders

sales@ipodix.com

For Business Collaboration

sales@ipodix.com

For CRO Services

sales@ipodix.com

For Technical Support

sales@ipodix.com
  • 50000+

    Recombinant Proteins

  • 100+

    Researchers

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US